Related Experiment Video

Updated: Jul 10, 2026

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy
07:52

A Mouse 5/6th Nephrectomy Model That Induces Experimental Uremic Cardiomyopathy

Published on: November 7, 2017

Cardiorenal anemia syndrome in chronic kidney disease

Der-Cherng Tarng1

  • 1Department and Institute of Physiology, National Yang-Ming University, Taipei, Taiwan, ROC. dctarng@vghtpe.gov.tw

Journal of the Chinese Medical Association : JCMA
|October 27, 2007
PubMed

Insights

Anemia is common in chronic kidney disease (CKD) and worsens with declining kidney function. Early diagnosis and treatment of anemia in CKD patients can improve quality of life and potentially slow disease progression.

Area of Science:

  • Nephrology
  • Hematology
  • Internal Medicine

Background:

  • Anemia is a common complication of chronic kidney disease (CKD), often progressing as renal function declines.
  • CKD patients with diabetes and hypertension face increased mortality risk due to anemia.
  • Anemia in CKD is frequently diagnosed late or undertreated, even after renal replacement therapy initiation.

Purpose of the Study:

  • To provide recommendations for the early diagnosis and management of anemia associated with CKD.
  • To emphasize the importance of timely anemia treatment in high-risk CKD patients with cardiovascular diseases.
  • To align clinical practice with international guidelines for managing CKD-related anemia.

Main Methods:

  • Review and synthesis of international practice guidelines on anemia in CKD.
  • Analysis of current literature on the impact of anemia on CKD progression and patient outcomes.
  • Development of practical recommendations for diagnosis and treatment thresholds.

Main Results:

  • Anemia significantly impacts quality of life and mortality in CKD patients.
  • Early detection and intervention for anemia in CKD are crucial for better patient outcomes.
  • Current recommendations suggest maintaining hemoglobin levels at or above 11 g/dL.

Conclusions:

  • Anemia of CKD requires earlier diagnosis and appropriate management to mitigate risks.
  • Optimizing anemia treatment in CKD may improve patient quality of life and delay end-stage renal disease.
  • Adherence to established guidelines is essential for effective CKD-related anemia care.

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Chronic Kidney Disease I: Introduction01:25

Chronic Kidney Disease I: Introduction

Chronic Kidney Disease (CKD) arises when the kidneys progressively lose their ability to function, ultimately leading to end-stage renal disease. At this advanced stage, the kidneys can no longer filter waste or maintain essential body functions, requiring renal replacement therapy (RRT) through dialysis or a kidney transplant for survival.Early-stage chronic kidney disease and detection challengesIn CKD's early stages, symptoms often remain absent because healthy nephrons compensate for...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...